SGLT2 Inhibitor-Related Polycythemia in a Patient With Chronic Heart Failure: A Potential Severe Adverse Event

Circ Heart Fail. 2023 Jul;16(7):e010613. doi: 10.1161/CIRCHEARTFAILURE.123.010613. Epub 2023 Jun 15.

Authors

Martijn Tukker¹, Ewout Bruwiere¹, Sven Bos², Kadir Caliskan¹

Affiliations

¹ Thoraxcenter, Department of Cardiology, Erasmus MC University Medical Center Rotterdam, the Netherlands (M.T., E.B., K.C.).
² Department of Haematology, Erasmus MC University Medical Center Rotterdam, the Netherlands (S.B.).

PMID: 37317887
DOI: 10.1161/CIRCHEARTFAILURE.123.010613

No abstract available

Keywords: adverse drug event; dapagliflozin; erythrocytosis; heart failure; polycythemia.

Publication types

Case Reports

MeSH terms

Diabetes Mellitus, Type 2*
Heart Failure* / chemically induced
Heart Failure* / diagnosis
Humans
Hypoglycemic Agents
Polycythemia* / chemically induced
Polycythemia* / diagnosis
Sodium-Glucose Transporter 2 Inhibitors* / adverse effects

Substances

Sodium-Glucose Transporter 2 Inhibitors
Hypoglycemic Agents